Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe

Open access

Abstract

Inhibiting the RAS oncogenic protein has largely been through targeting the switch regions that interact with signalling effector proteins. Here, we report designed ankyrin repeat proteins (DARPins) macromolecules that specifically inhibit the KRAS isoform by binding to an allosteric site encompassing the region around KRAS-specific residue histidine 95 at the helix α3/loop 7/helix α4 interface. We show that these DARPins specifically inhibit KRAS/effector interactions and the dependent downstream signalling pathways in cancer cells. Binding by the DARPins at that region influences KRAS/effector interactions in different ways, including KRAS nucleotide exchange and inhibiting KRAS dimerization at the plasma membrane. These results highlight the importance of targeting the α3/loop 7/α4 interface, a previously untargeted site in RAS, for specifically inhibiting KRAS function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-10419-2

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 DARPins K13 and K19 bind KRAS to a novel allosteric site. a X-ray crystal structures of KRASG12V-GDP-bound to DARPin K13 (PDB 6H46) and KRASG12V-GDP-bound to DARPin K19 (PDB 6H47) with the indication of RAS switch regions, helix 3 (α3), helix 4 (α4) and loop 7 (L7) regions. b Expanded view of the interaction between the DARPin K13 and KRAS around histidine residue 95 of KRAS
Fig. 1 DARPins K13 and K19 bind KRAS to a novel allosteric site. a X-ray crystal structures of KRASG12V-GDP-bound to DARPin K13 (PDB 6H46) and KRASG12V-GDP-bound to DARPin K19 (PDB 6H47) with the indication of RAS switch regions, helix 3 (α3), helix 4 (α4) and loop 7 (L7) regions. b Expanded view of the interaction between the DARPin K13 and KRAS around histidine residue 95 of KRASCC BY · PubMed Central
Fig. 2 HSQC NMR chemical shift changes in KRAS after DARPin K19 binding. a Comparison between 1H, 15N TROSY spectra for apo KRASG12V at 100 μM (black) overlaid with K19-bound KRASG12V at 89 μM (green). DARPin concentrations were in slight excess. An expanded region is shown on the right. b Amino acids undergoing chemical shifts upon DARPin K19 binding on KRASG12V-GDP are shown in blue, residues not experiencing shifts are shown in turquoise in the KRASG12V sequence (unassigned residues are not highlighted). The P-loop is highlighted in yellow, the switch 1 in dark yellow and the switch 2 in purple. c Ribbon representation of (b) with amino acids undergoing chemical shifts in blue and residues not experiencing shifts in turquoise in the KRASG12V-GDP structure (PDB 4TQ9) after DARPin K19 binding (unassigned residues are in grey). L7: loop 7, α3: helix 3, α4: helix 4
Fig. 2 HSQC NMR chemical shift changes in KRAS after DARPin K19 binding. a Comparison between 1H, 15N TROSY spectra for apo KRASG12V at 100 μM (black) overlaid with K19-bound KRASG12V at 89 μM (green). DARPin concentrations were in slight excess. An expanded region is shown on the right. b Amino acids undergoing chemical shifts upon DARPin K19 binding on KRASG12V-GDP are shown in blue, residues not experiencing shifts are shown in turquoise in the KRASG12V sequence (unassigned residues are not highlighted). The P-loop is highlighted in yellow, the switch 1 in dark yellow and the switch 2 in purple. c Ribbon representation of (b) with amino acids undergoing chemical shifts in blue and residues not experiencing shifts in turquoise in the KRASG12V-GDP structure (PDB 4TQ9) after DARPin K19 binding (unassigned residues are in grey). L7: loop 7, α3: helix 3, α4: helix 4CC BY · PubMed Central
Fig. 3 K13 and K19 are KRAS selective binders. a BRET donor saturation assay between KRASG12D or KRASS17N (donors) and the DARPins (acceptors). b BRET donor saturation assay between KRASWT, NRASWT, NRASQ61H, HRASWT or HRASG12V (donors) and the DARPins (acceptors). c Co-immunoprecipitation of 3xFLAG-KRASWT, −NRASWT and −HRASWT with the DARPin-GFP2 fusions in 10% foetal bovine serum. IP Immunoprecipitation, WCE whole-cell extract. d BRET donor saturation assay between KRASWT, KRASH95Q, KRASH95L or KRASE107D (donors) and the DARPins (acceptors). Note that most of the donor saturation curves with K27 as acceptor are overlapping in panels b and d. Each experiment was performed three times (a–d). Error bars are mean ± SD of biological repeats. c Source data are provided as a Source Data file
Fig. 3 K13 and K19 are KRAS selective binders. a BRET donor saturation assay between KRASG12D or KRASS17N (donors) and the DARPins (acceptors). b BRET donor saturation assay between KRASWT, NRASWT, NRASQ61H, HRASWT or HRASG12V (donors) and the DARPins (acceptors). c Co-immunoprecipitation of 3xFLAG-KRASWT, −NRASWT and −HRASWT with the DARPin-GFP2 fusions in 10% foetal bovine serum. IP Immunoprecipitation, WCE whole-cell extract. d BRET donor saturation assay between KRASWT, KRASH95Q, KRASH95L or KRASE107D (donors) and the DARPins (acceptors). Note that most of the donor saturation curves with K27 as acceptor are overlapping in panels b and d. Each experiment was performed three times (a–d). Error bars are mean ± SD of biological repeats. c Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 4 K13/K19 prevent KRAS/effector interactions in cells. a BRET competition assays between KRASG12D/effector domain interactions and the DARPins used as competitors. The effector domains used were PI3Kα RBD, PI3Kγ RBD, CRAF RBD and RALGDS RAS-associating (RA) domain. b–d BRET competition assays between CRAFFL/KRASG12D (b), NRASQ61H (c) and HRASG12V (d) interactions with the DARPins used as competitors. E3.5 is a negative control, and DARPin K27 is a positive control. Statistical analyses in a–d were performed using a one-way ANOVA followed by Dunnett’s post-hoc tests (***P < 0.001, ****P < 0.0001, ns not significant). Each experiment was performed three times (a–d). Error bars are mean ± SD of biological repeats. a–d Source data are provided as a Source Data file
Fig. 4 K13/K19 prevent KRAS/effector interactions in cells. a BRET competition assays between KRASG12D/effector domain interactions and the DARPins used as competitors. The effector domains used were PI3Kα RBD, PI3Kγ RBD, CRAF RBD and RALGDS RAS-associating (RA) domain. b–d BRET competition assays between CRAFFL/KRASG12D (b), NRASQ61H (c) and HRASG12V (d) interactions with the DARPins used as competitors. E3.5 is a negative control, and DARPin K27 is a positive control. Statistical analyses in a–d were performed using a one-way ANOVA followed by Dunnett’s post-hoc tests (***P < 0.001, ****P < 0.0001, ns not significant). Each experiment was performed three times (a–d). Error bars are mean ± SD of biological repeats. a–d Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 5 K13/K19 inhibitory potency in cells. a Western blot analyses of the activation state of the RAF/MEK/ERK and PI3K/AKT pathways in cancer cell lines bearing or not a mutated RAS upon overexpression of the DARPin-mCherry fusions. E3.5 is a negative and DARPin K27 is a positive control. b Quantifications of pERK/ERK, pMEK/MEK and pAKT/AKT signals from (a). These signals were normalised to the negative control DARPin E3.5. Statistical analyses in b were performed using a one-way ANOVA followed by Dunnett’s post-hoc tests (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Each experiment was performed at least four times (a–b). Error bars are mean ± SEM of biological repeats (b). a, b Source data are provided as a Source Data file
Fig. 5 K13/K19 inhibitory potency in cells. a Western blot analyses of the activation state of the RAF/MEK/ERK and PI3K/AKT pathways in cancer cell lines bearing or not a mutated RAS upon overexpression of the DARPin-mCherry fusions. E3.5 is a negative and DARPin K27 is a positive control. b Quantifications of pERK/ERK, pMEK/MEK and pAKT/AKT signals from (a). These signals were normalised to the negative control DARPin E3.5. Statistical analyses in b were performed using a one-way ANOVA followed by Dunnett’s post-hoc tests (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Each experiment was performed at least four times (a–b). Error bars are mean ± SEM of biological repeats (b). a, b Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 6 K13 and K19 inhibit KRAS nucleotide exchange. a KRAS biochemical coupled assay for inhibition of nucleotide exchange or KRAS/CRAF RBD interaction by DARPins K13, K19 or negative control DARPin E3.5. KRASG12V loaded with GDP was incubated for 15 min with a dilution series of DARPins K13, K19, K27 or E3.5. SOS and GTPγS were added to allow nucleotide exchange, followed by CRAF RBD. The KRASG12V-GTPγS/CRAF RBD complex was quantitated by the FRET signal. b KRAS/CRAF RBD inhibition assay testing DARPins K13, K19, K55 (a known KRAS/CRAF RBD inhibitor) and E3.5. The FRET signal was measured for the interaction between CRAF RBD and KRASG12V loaded with GTPγS and inhibition of the signal monitored at varying concentrations of DARPins K13, K19, K55 and E3.5. Error bars represent the mean ± SD (n = 3). c MANT dGDP and MANT GTP nucleotide exchange and release assays. SOS-mediated exchange of MANT-labelled dGDP or GTP on KRASG12V was studied over time upon addition of 10 μM concentrations of DARPins. Included controls were previously published RAS-binding DARPins K55 (non-inhibitor of nucleotide exchange) and K27 (inhibitor of nucleotide exchange). For release assays, DARPins were added after equilibration of MANT nucleotides. In these assays, the binding of MANT-labelled nucleotides to KRASG12V results in an increase in fluorescence, detected by measuring light emission at a wavelength of 450 nm. Error bars represent the mean ± SD (n = 8). d Superimposition of K19/KRASG12V-GDP (PDB 6H47) and SOScat structures (PDB 1BKD)
Fig. 6 K13 and K19 inhibit KRAS nucleotide exchange. a KRAS biochemical coupled assay for inhibition of nucleotide exchange or KRAS/CRAF RBD interaction by DARPins K13, K19 or negative control DARPin E3.5. KRASG12V loaded with GDP was incubated for 15 min with a dilution series of DARPins K13, K19, K27 or E3.5. SOS and GTPγS were added to allow nucleotide exchange, followed by CRAF RBD. The KRASG12V-GTPγS/CRAF RBD complex was quantitated by the FRET signal. b KRAS/CRAF RBD inhibition assay testing DARPins K13, K19, K55 (a known KRAS/CRAF RBD inhibitor) and E3.5. The FRET signal was measured for the interaction between CRAF RBD and KRASG12V loaded with GTPγS and inhibition of the signal monitored at varying concentrations of DARPins K13, K19, K55 and E3.5. Error bars represent the mean ± SD (n = 3). c MANT dGDP and MANT GTP nucleotide exchange and release assays. SOS-mediated exchange of MANT-labelled dGDP or GTP on KRASG12V was studied over time upon addition of 10 μM concentrations of DARPins. Included controls were previously published RAS-binding DARPins K55 (non-inhibitor of nucleotide exchange) and K27 (inhibitor of nucleotide exchange). For release assays, DARPins were added after equilibration of MANT nucleotides. In these assays, the binding of MANT-labelled nucleotides to KRASG12V results in an increase in fluorescence, detected by measuring light emission at a wavelength of 450 nm. Error bars represent the mean ± SD (n = 8). d Superimposition of K19/KRASG12V-GDP (PDB 6H47) and SOScat structures (PDB 1BKD)CC BY · PubMed Central
Fig. 7 K13/K19 selectively prevent KRAS dimerisation. BRET competition assays with homodimerisation of (a) KRASG12D; (b) of NRASQ61H and (c) of HRASG12V using DARPins K13 or K19 as competitors and DARPin E3.5 as non-binding negative control. Statistical analyses in a–c were performed using a one-way ANOVA followed by Dunnett’s post-hoc tests (**P < 0.01, ***P < 0.001, ****P < 0.0001). Each experiment was performed four times (a–c). Error bars are mean ± SD of biological repeats. a–c Source data are provided as a Source Data file
Fig. 7 K13/K19 selectively prevent KRAS dimerisation. BRET competition assays with homodimerisation of (a) KRASG12D; (b) of NRASQ61H and (c) of HRASG12V using DARPins K13 or K19 as competitors and DARPin E3.5 as non-binding negative control. Statistical analyses in a–c were performed using a one-way ANOVA followed by Dunnett’s post-hoc tests (**P < 0.01, ***P < 0.001, ****P < 0.0001). Each experiment was performed four times (a–c). Error bars are mean ± SD of biological repeats. a–c Source data are provided as a Source Data fileCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 98

Metadata

Authors
Bery, N., Legg, S., Debreczeni, J., Breed, J., Embrey, K., Stubbs, C., Kolasinska-Zwierz, P., Barrett, N., Marwood, R., Watson, J., Tart, J., Overman, R., Miller, A., Phillips, C., Minter, R., & Rabbitts, T. H.
Affiliations
  • AstraZeneca (United Kingdom) (GB)
  • John Radcliffe Hospital (GB)
Corresponding author
Rabbitts, Terence H.
Venue
Nature Communications
Published
2019-06-13
Volume
10
Issue
1
Pages
2607-2607
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2950908936
Cited by
97
References
38
Citations by year
2026: 9 · 2025: 11 · 2024: 8 · 2023: 20 · 2022: 12 · 2021: 13 · 2020: 17 · 2019: 6
FWCI
3.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • HAL (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Wellcome Trust (099246/Z/12/Z)
  • RCUK | Medical Research Council (MR/J000612/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
KRAS inhibition, DARPin, allosteric site, oncogenic Ras
MeSH terms
Allosteric Site, Antineoplastic Agents, Cell Membrane, Drug Screening Assays, Antitumor, Histidine, Humans, Isoenzymes, Neoplasms, Protein Binding, Drug Design, Signal Transduction, Proto-Oncogene Proteins p21(ras), Ankyrin Repeat, Peptide Library, Cell Line, Tumor, Protein Multimerization, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe. https://app.cochat.ai/papers/10.1038/s41467-019-10419-2
The paper
Bery, N., Legg, S., Debreczeni, J., Breed, J., Embrey, K., Stubbs, C., Kolasinska-Zwierz, P., Barrett, N., Marwood, R., Watson, J., Tart, J., Overman, R., Miller, A., Phillips, C., Minter, R., & Rabbitts, T. H. (2019). KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe. Nature Communications. https://doi.org/10.1038/s41467-019-10419-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.